Giulio C Spagnoli Selected Research

Antigens

01/2007	Cancer/testis antigen expression and specific cytotoxic T lymphocyte responses in non small cell lung cancer.
01/2007	Expression of cancer-testis (CT) antigens in placenta.
01/2007	Cancer/testis (CT) antigens are expressed in fetal ovary.
11/2006	Effect of IL-1 on the hydrolysis of the tumor antigen epitope gp100(280-288) by fibroblast-expressed enzymes.
08/2006	Permeability of phospholipid vesicles to the tumor antigen epitope gp100(280-288).
02/2006	Expression and possible prognostic role of MAGE-A4, NY-ESO-1, and HER-2 antigens in women with relapsing invasive ductal breast cancer: retrospective immunohistochemical study.
01/2006	Characterization of highly frequent epitope-specific CD45RA+/CCR7+/- T lymphocyte responses against p53-binding domains of the human polyomavirus BK large tumor antigen in HLA-A*0201+ BKV-seropositive donors.
12/2005	Culture of melanoma cells in 3-dimensional architectures results in impaired immunorecognition by cytotoxic T lymphocytes specific for Melan-A/MART-1 tumor-associated antigen.
07/2005	NY-ESO-1/LAGE-1 coexpression with MAGE-A cancer/testis antigens: a tissue microarray study.
06/2005	Active antigen-specific immunotherapy of melanoma: from basic science to clinical investigation.
01/2005	Expression of cancer-testis antigens in endometrial carcinomas using a tissue microarray.
06/2004	Hydrolysis of the tumor-associated antigen epitope gp100(280-288) by membrane-associated and soluble enzymes expressed by immature and mature dendritic cells.
03/2004	Degradation of the tumor antigen epitope gp100(280-288) by fibroblast-associated enzymes abolishes specific immunorecognition.
01/2004	Ex vivo characterization of tumor-derived melanoma antigen encoding gene-specific CD8+cells in patients with hepatocellular carcinoma.
12/2003	Expression of the MAGE-A4 and NY-ESO-1 cancer-testis antigens in serous ovarian neoplasms.
02/2003	Cancer/testis tumour-associated antigens: immunohistochemical detection with monoclonal antibodies.
01/2003	Expression of cancer/testis tumor associated antigens in cervical squamous cell carcinoma.
12/2002	Tissue microarray evaluation of Melanoma antigen E (MAGE) tumor-associated antigen expression: potential indications for specific immunotherapy and prognostic relevance in squamous cell lung carcinoma.
09/2002	Cancer-testis antigen expression in uterine malignancies with an emphasis on carcinosarcomas and papillary serous carcinomas.
08/2002	Prognostic relevance of MAGE-A4 tumor antigen expression in transitional cell carcinoma of the urinary bladder: a tissue microarray study.
03/2002	Rapid induction of specific cytotoxic T lymphocytes against melanoma-associated antigens by a recombinant vaccinia virus vector expressing multiple immunodominant epitopes and costimulatory molecules in vivo.
02/2002	MAGE antigen expression in monophasic and biphasic synovial sarcoma.

Articles by Research Topic

Disease

12	Neoplasms (Cancer) 09/2007 - 08/2002
11	Melanoma (Melanoma, Malignant) 07/2008 - 01/2002
9	Testicular Neoplasms (Testicular Cancer) 01/2007 - 09/2002
2	Human Influenza (Influenza) 03/2008 - 01/2004
1	Small Cell Carcinoma 01/2007
1	Breast Neoplasms (Breast Cancer) 02/2006
1	Endometrial Neoplasms (Endometrial Cancer) 01/2005
1	Hepatocellular Carcinoma (Hepatoma) 01/2004
1	Ovarian Neoplasms (Ovarian Cancer) 12/2003
1	Squamous Cell Carcinoma (Epidermoid Carcinoma) 01/2003
1	Carcinosarcoma 09/2002
1	Carcinoma (Carcinomatosis) 09/2002
1	Transitional Cell Carcinoma 08/2002
1	Synovial Sarcoma (Synovioma) 02/2002

Drug/Important Bio-Agent (IBA)

22	AntigensIBA 01/2007 - 02/2002
4	VirosomesIBA 03/2008 - 01/2004
3	EnzymesIBA 11/2006 - 03/2004
2	InterferonsIBA 06/2002 - 01/2002
1	Carbon MonoxideIBA 03/2008
1	EpitopesIBA 03/2008
1	H-cadherin (T-cadherin)IBA 09/2007
1	Interleukin-1 (Interleukin 1)IBA 11/2006
1	Cancer VaccinesIBA 01/2006
1	HLA-A Antigens (HLA-A)IBA 01/2006
1	HLA-A0201 antigenIBA 12/2005
1	Monoclonal AntibodiesIBA 02/2003
1	Cadherins (E-Cadherin)IBA 06/2002
1	Immunodominant EpitopesIBA 03/2002

Therapy/Procedure

5	Immunotherapy 07/2008 - 06/2005